Why have CD19 CAR-T therapy in China specifically?

China offers this therapy at approximately $130,000, significantly lower than in the US or Europe, where costs can exceed $400,000. Chinese hospitals use the same approved CAR-T product (relmacabtagene/lis-cel) and follow international safety protocols. Many centers have high patient volumes, meaning oncologists have extensive experience managing side effects like CRS. Additionally, China’s medical infrastructure supports comprehensive multidisciplinary care during the 3–4 week inpatient stay.